Diagnosis and treatment of post‐transplantation lymphoproliferative disorder in pediatric heart transplant patients
- 6 January 2009
- journal article
- Published by Wiley in Pediatric Transplantation
- Vol. 13 (1) , 54-62
Abstract
Abstract: PTLD is a severe complication in transplant recipients. Detection of increased EBV load in the peripheral blood acts as a surrogate marker for increased risk of PTLD development. We analyzed the time course of the disease, its severitiy, the organs involved, and mortality rates in our institutional experience of pediatric heart transplantation. This paper identifies risk factors for PTLD and describes the different ways of diagnosing and treating the disease. PTLD was screened for in 146 pediatric heart transplant patients using a retrospective analysis in patients who received transplantation before 1998. Prospective determination was performed in 72/146 patients transplanted after 1998 within the post‐transplant follow‐up. The occurrence of PTLD with all interventions, including tapering of immunosuppression, surgery, viral monitoring, and antiviral interventions, was recorded. PTLD was diagnosed in 12/147 (8.2%) children at a mean age of 7.2 ± 3.3 yr after a mean post‐transplant period of 3.2 ± 2.2 yr. PTLD manifested in: lymph nodes (n = 4), intestine (n = 3), tonsils and adenoids (n = 2), eye (n = 2), and lung (n = 1). It was diagnosed in 7/12 as a monomorphic B‐cell lymphoma and in four patients as a monomorphic Burkitt lymphoma, a polymorphic B‐cell lymphoma, a T‐cell rich or angiocentric lymphoma (Liebow) and as reactive plasmacytic hyperplasia (early lesion), respectively. Histology was not possible in one patient with ocular manifestation. EBV association was 83%. Risk factors in the comparison with patients without PTLD were age at time of Tx, primary EBV infection after Tx, use of Azathioprine and ≥3 doses of ATG. CMV mismatch and CMV infection, rejection episodes and steroids were not risk factors. Despite reduction of immunosuppression, treatment consisted of surgical procedures to remove tumor masses (n = 6), Rituximab (n = 5), polychemotherapy (n = 3), antiviral (n = 1) and autologous T‐cell therapy (n = 1). All patients demonstrated full remission without death related to PTLD or treatment at 3.9 (1.3–6.2) yr median follow‐up time. The manifestation of PTLD in pediatric heart transplant recipients is associated with EBV infection and is predominantly in the form of a B‐cell lymphoma. A tight and specific follow‐up including early assessment of immunity status and specific therapeutic intervention to improve cellular immunity is warranted and may contribute to a significant reduction of PTLD‐related morbidity and mortality.Keywords
This publication has 41 references indexed in Scilit:
- Ultrasound in Abdominal and Soft-Tissue Childhood PTLD (Post-Transplant Lymphoproliferative Disease)Ultraschall in der Medizin - European Journal of Ultrasound, 2007
- Constitutive activation of mTOR signaling pathway in post-transplant lymphoproliferative disordersLaboratory Investigation, 2007
- Treatment of solid organ transplant recipients with autologous Epstein Barr virus–specific cytotoxic T lymphocytes (CTLs)Blood, 2006
- Post-Transplant Lymphoproliferative Disorders Occurring After Renal Transplantation in Adults: Report of 230 Cases From the French RegistryAmerican Journal of Transplantation, 2006
- Post‐transplant lymphoproliferative disorder following pediatric heart transplantationPediatric Transplantation, 2005
- Sirolimus in pediatric patients: Results in the first 6 months post‐renal transplantPediatric Transplantation, 2005
- Lung Retransplantation After Posttransplantation Lymphoproliferative Disorder (PTLD): A Single-Center Experience and Review of Literature of PTLD in Lung Transplant RecipientsThe Journal of Heart and Lung Transplantation, 2005
- Dual monoclonal antibody therapy for the treatment of PTLD?Pediatric Transplantation, 2003
- Is posttransplant lymphoproliferative disorder (PTLD) caused by any specific immunosuppressive drug or by the transplantation per se?Transplantation, 2003
- Statistical analysis of proliferative index data in clinical trialsStatistics in Medicine, 1994